User:Mr. Ibrahem/Fingolimod

Mr. Ibrahem/Fingolimod
Clinical data
Trade names	Gilenya
AHFS/Drugs.com	Monograph
MedlinePlus	a611006
License data	EU EMA: by INN; US DailyMed: Fingolimod; US FDA: Fingolimod;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth (capsules)
Drug class	Immunosuppressants
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;
Chemical and physical data
Formula	C19H33NO2
Molar mass	307.478 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;
	InChI InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3 ; Key:KKGQTZUTZRNORY-UHFFFAOYSA-N ;
	(what is this?) (verify)

Fingolimod, sold under the brand name Gilenya, is a medication, mostly used to treat multiple sclerosis (MS).^[1] It reduces relapses in relapsing-remitting MS by approximately one-half over a two-year period.^[3] It may also be used for chronic inflammatory demyelinating polyneuropathy.^[1] It is taken by mouth.^[2]

Common side effects include headache, liver problems, diarrhea, nausea, cough, and pain.^[1] Other side effects may include AV block, infection, allergic reactions, skin cancer, lung problems, progressive multifocal leukoencephalopathy, and posterior reversible encephalopathy syndrome.^[1] Use in pregnancy may harm the baby.^[1] It is a sphingosine-1-phosphate receptor modulator, which prevents T cells from travelling from lymph nodes to the brain and spinal cord.^[4]

Fingolimod was approved for medical use in the United States in 2010 and Europe in 2011.^[1]^[4] In the United Kingdom 4 weeks of treatment costs the NHS about £1,470 as of 2021.^[2] This amount in the United States costs about 8,300 USD.^[5] A generic version was approved in 2021 in the USA.^[6]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h "Fingolimod Monograph for Professionals". Drugs.com. Archived from the original on 16 June 2018. Retrieved 10 December 2021.
^ ^a ^b ^c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 901. ISBN 978-0857114105.
^ Sanford M (August 2014). "Fingolimod: a review of its use in relapsing-remitting multiple sclerosis". Drugs. 74 (12): 1411–33. doi:10.1007/s40265-014-0264-y. PMID 25063048. S2CID 42807019.
^ ^a ^b "Gilenya". Archived from the original on 29 September 2021. Retrieved 10 December 2021.
^ "Gilenya Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 17 May 2020. Retrieved 10 December 2021.
^ Research, Center for Drug Evaluation and (10 February 2022). "2021 First Generic Drug Approvals". FDA. Archived from the original on 21 June 2022. Retrieved 22 October 2022.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h "Fingolimod Monograph for Professionals". Drugs.com. Archived from the original on 16 June 2018. Retrieved 10 December 2021.

[BNF81-2] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 901. ISBN 978-0857114105.

[3] Sanford M (August 2014). "Fingolimod: a review of its use in relapsing-remitting multiple sclerosis". Drugs. 74 (12): 1411–33. doi:10.1007/s40265-014-0264-y. PMID 25063048. S2CID 42807019.

[EPAR2021-4] "Gilenya". Archived from the original on 29 September 2021. Retrieved 10 December 2021.

[5] "Gilenya Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 17 May 2020. Retrieved 10 December 2021.

[6] Research, Center for Drug Evaluation and (10 February 2022). "2021 First Generic Drug Approvals". FDA. Archived from the original on 21 June 2022. Retrieved 22 October 2022.

[1]

[3]

[2]

[4]

[5]

[6]